What happens when you stop taking a GLP-1

What this article leaves out, on purpose

We only state things we can source. Several questions people search alongside this one are not covered by our source set, and we are not going to estimate them:

• how long the drug takes to clear the body after a last dose
• when appetite or "food noise" returns, and in what order
• average real-world regain outside of clinical trials, including among people who restart or switch later
• whether blood sugar, blood pressure, or lipid changes reverse, and how quickly
• whether tapering the dose down produces a different outcome than stopping abruptly
• whether having taken the drug causes any lasting metabolic change after stopping

That last one is the fear we hear most, and we would rather tell you we cannot cite an answer than hand you a reassuring sentence with nothing behind it. If you see week-by-week timelines elsewhere, ask which study they came from.

Why you are stopping changes what happens next

You are stopping because of side effects

Side effects are a common reason people come off. In the SELECT trial (published results reviewed August 2026), adverse events leading to permanent discontinuation of treatment occurred in 16.6% of semaglutide recipients versus 8.2% of placebo recipients. The SELECT trial enrolled 17,604 patients aged 45 years or older with preexisting cardiovascular disease and a body-mass index of 27 or greater, but with no history of diabetes, over a mean follow-up of 39.8 months.

The most common adverse reactions reported in at least 5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. Most of that list is gastrointestinal, and managing nausea on a GLP-1 has its own guide. In the Zepbound weight-reduction trials, nausea was reported by 25% of patients on 5 mg, 29% on 10 mg, and 28% on 15 mg, versus 8% on placebo (label reviewed August 2026).

Tell the prescriber which symptom is the problem before you decide. What happens next is a clinical conversation, not a rule you can look up.

The drug is treating something other than weight

This is the case where stopping is not primarily a weight decision, and it is the one to raise with a clinician first.

• OZEMPIC injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• OZEMPIC injection is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
• OZEMPIC injection is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
• Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
• Zepbound is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
• Wegovy injection is indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3) in adults, under accelerated approval; this indication does not apply to Wegovy tablets.

If any of those describe you, the question is not "how much weight will I regain." It is what happens to the condition being treated. Raise it with the prescriber before you change or stop anything.

A clinician has told you to stop

Sometimes stopping is the correct clinical answer and is not up for negotiation. Acute pancreatitis has occurred in clinical trials with semaglutide; Wegovy should be discontinued promptly if pancreatitis is suspected and should not be restarted if pancreatitis is confirmed.

Cost, a denial, or a lapsed coupon

This is a different problem wearing the same clothes. Nothing clinical has changed. The access did. That is the section below.

If cost or a denial is the reason

Being forced off is not the same as choosing to stop, and there are formal processes with hard deadlines attached. Preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug, and a denial is not the end of the process.

Two different clocks are running, and they are easy to confuse. The first is how long the plan has to decide your original claim and tell you the answer.

The second clock starts only once you appeal, and it runs on its own separate deadlines.

Deadlines as published by HealthCare.gov, checked August 7, 2026. These are the federal rules for most non-grandfathered private plans. Medicare, Medicaid, TRICARE, VA coverage, and some grandfathered plans run their own appeals processes on different timelines. Your plan documents govern, not this table.

On that filing fee: the plan or issuer, not you, pays the independent reviewer. Only states that expressly allowed a filing fee as of November 18, 2015 may still charge one, and where a fee applies it must be refunded if the denial is reversed, waived if paying it would cause you financial hardship, and capped at $75 per claimant per plan year.

You may also not have to finish the internal appeal first. An internal appeal is treated as exhausted — letting you go straight to external review — if the plan waives it, in urgent-care situations, or if the plan fails to follow the internal appeals rules in more than a minor way.

One thing worth knowing before you count on an external review: as of July 1, 2026, the HHS-Administered Federal External Review Process is temporarily unavailable, and HHS has said it will publish more information about extending deadlines for people affected. This applies if you live in Alabama, Florida, Georgia, Texas, Wisconsin, or a U.S. territory other than Puerto Rico and your plan uses the federal process. If that is you, follow the instructions in the notice from your plan about where to request a review, and do not assume the four-month deadline has been paused until HHS says so in writing.

Three things matter if you are trying not to have a gap in supply.

Continued coverage during an appeal. Federal rules require plans and issuers to provide continued coverage pending the outcome of an appeal. Read the scope carefully, because it is narrower than it sounds. The rule works by requiring compliance with 29 CFR 2560.503-1(f)(2)(ii): where a plan has approved an ongoing course of treatment, it must give you an opportunity to appeal before reducing or terminating that coverage. So it protects treatment you are already approved for. It is not a rule that makes a plan cover a drug it never approved in the first place, and it does not apply where the reduction comes from the plan itself being amended or terminated.

Ask about a one-time refill. Some insurers provide a one-time refill after you first enroll. HealthCare.gov's advice is to ask your insurance company whether they offer one, which buys you time to talk to your prescriber instead of stopping the same week.

The drug exceptions process. You have the right to follow your insurer's drug exceptions process to get a drug that is not normally covered. Generally your doctor has to confirm to the plan that the drug is appropriate for your condition because other covered drugs have not been or will not be as effective, or because covered alternatives have caused or are likely to cause harmful side effects. While you are in the exceptions process, the plan may give you access to the drug until a decision is made — may, not must, so ask rather than assume. If the exception is granted, the plan generally treats the drug as covered at the copay for its most expensive tier, and what you pay counts toward your deductible and out-of-pocket maximum.

Measured's insurance concierge team submits prior authorizations on the patient's behalf and keeps the patient updated on the insurance plan's determination, and for patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the patient's plan. Coverage depends on your specific plan and benefits. No process guarantees an approval.

If you have Medicare

The Medicare GLP-1 Bridge is a short-term CMS demonstration running from July 1, 2026 through December 31, 2027. It covers three products: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound — KwikPen only. The single-dose Zepbound pen and Zepbound vials are not covered.

The cost is $50 per month regardless of income level. Read the rest before treating that as a straightforward win: that $50 does not count toward your Medicare drug plan deductible or your yearly out-of-pocket limit, the drugs are not eligible for the Medicare Prescription Payment Plan, and the program provides no low-income subsidy. If you currently receive a low-income subsidy, the Bridge may cost you more than your existing coverage rather than less.

Eligibility is narrow. Medicare's fact sheet requires all four of the following:

• You have Medicare Part D coverage — and not solely through certain plan types, such as private fee-for-service plans, cost contract plans, or a PACE organization.
• You are not eligible to get a GLP-1 through your Medicare drug plan. If your plan already pays for one, you have to keep getting it that way.
• You do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Medicare directs people with those conditions back to their drug plan, which may already cover a GLP-1 for them.
• You are at least 18, and your BMI is 35 or higher; or 30 or higher with certain types of heart failure, high blood pressure that is hard to control, or chronic kidney disease (stage 3a or above); or 27 or higher with prediabetes, or a prior heart attack, stroke, or blocked arteries in the legs or arms.

That third requirement is worth reading against the section earlier on this page. If your GLP-1 is treating type 2 diabetes, obstructive sleep apnea, or liver disease, the Bridge is not your fallback — those conditions disqualify you from it, and the route back to coverage runs through your Part D plan instead.

If you do qualify, the process is: your prescriber sends a prescription, the pharmacy confirms your eligibility and will need your Medicare ID number, your prescriber submits an approval form to Medicare, and Medicare sends you a letter confirming coverage. Refills do not require a new approval as long as you stay on the same drug, even if your dose changes.

This is a demonstration, so terms and the product list can change. Confirm at Medicare.gov or 1-800-MEDICARE before planning around it. Details above are from Medicare fact sheet CMS Product No. 12234 (June 2026) and CMS program materials, checked August 7, 2026.

Cash pricing exists as well, but manufacturer self-pay prices are promotional and they move. As of August 7, 2026, Novo Nordisk listed self-pay pricing for the Wegovy pill at $149 per month for the 1.5 mg and 4 mg doses, with the 4 mg price scheduled to rise to $199 per month after August 31, 2026. The injection carries separate introductory pricing that reverts to a substantially higher monthly price once the introductory fills are used. Eligibility and restrictions apply, and the manufacturer can change or cancel these programs at any time. Measured lists a compounded semaglutide option that does not require insurance, with medication included in the membership price, from $119/mo as of August 2026. Check current terms directly rather than planning around any number on a page, including this one.

A compounded medication is not the same thing as a cheaper version of the brand. Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness, or quality. Whether a compounded option is appropriate for you, and whether it is available at all, is a decision for your prescriber.

Do not assume dosage forms are interchangeable. Strengths and dosing instructions differ between an injection and a tablet, so be specific with your prescriber about what you are switching to. Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. Zepbound is administered exclusively as a subcutaneous injection; the FDA label describes it only as 'injection, for subcutaneous use' and no oral dosage form of Zepbound is listed in the label.

Stopping is not the same as missing a dose

A late dose is a scheduling question, not a discontinuation. If a Zepbound dose is missed, patients should administer it as soon as possible within 4 days (96 hours) after the missed dose; if more than 4 days have passed, the missed dose is skipped and the regular weekly schedule resumed. A missed Mounjaro dose should be administered as soon as possible within 4 days (96 hours) of the missed dose; if more than 4 days have passed, the missed dose is skipped and the next dose given on the regularly scheduled day.

If the problem is that the injection day never fits your week, that is fixable without stopping. The day of weekly Zepbound administration can be changed if necessary, as long as the time between two doses is at least 3 days (72 hours). Check the label for your own product, since these instructions are product-specific.

Before you stop

Message the prescriber first, and say plainly which of these you are: stopping because of a symptom, stopping because of cost, or stopping because you reached a goal. The three lead to different conversations. If the medication is treating type 2 diabetes, cardiovascular risk, kidney disease, obstructive sleep apnea, or liver disease, do not stop on your own — those are labeled indications, and the prescriber needs to weigh what happens to the condition being treated.

Disclosure: Measured prescribes FDA-approved GLP-1 medications and compounded alternatives. We have a commercial interest in patients staying on treatment, which is exactly why the sections above are limited to what we can cite and why the gaps are labeled as gaps.